The Danish pharmaceutical giant is putting up ... keep the alliance from spreading into areas where Ascendis’s internal pipeline already has product candidates. But Novo Nordisk has exclusive ...

Ascendis Pharma (ASND) Company Description: Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. Through its TransCon technology, it develops a ...

In a deal worth up to $285 million initially for the lead program, Novo Nordisk will gain access to Ascendis’ TransCon ...

Metsera has brought in over $500m in funding in just seven months as it looks to enter the competitive weight loss arena.

Novo Nordisk has signed off on a $285 million biobucks deal with fellow Denmark-based company Ascendis Pharma to help the Wegovy manufacturer develop a once-monthly GLP-1 receptor agonist.

The agreement could bring Ascendis up to $285 million in milestone payments, along with sales-based royalties. Novo Nordisk will handle the clinical development and commercialization, with ...

Novo Nordisk and Ascendis Pharma have partnered to develop therapies for metabolic and cardiovascular diseases, including a once-monthly GLP-1 receptor agonist that will initially target type 2 ...

Under the deal, Ascendis will handle the first development of TransCon-based candidates and get up to $285 million in upfront and milestone payments for the lead program. Based on regulatory and ...

Revenue for the quarter came in at... Investing.com - Ascendis Pharma (NASDAQ:ASND) AS reported on Wednesday first quarter earnings that beat analysts' forecasts and revenue that topped expectations.